Nautilus Biotechnolgy, Inc. (NAUT) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nautilus Biotechnology, Inc. faces a significant risk of its Common Stock being delisted from Nasdaq due to non-compliance with the Minimum Bid Price Requirement. This situation could adversely affect the company’s ability to sell equity securities and the liquidity of its stock. Despite efforts to transfer its listing to the Nasdaq Capital Market and potentially conduct a reverse stock split, there is no assurance of regaining compliance. Delisting could lead to reduced market quotations, liquidity, and trading activity, as well as hinder future financing opportunities.
Overall, Wall Street has a Moderate Buy consensus rating on NAUT stock based on 2 Buys.
To learn more about Nautilus Biotechnolgy, Inc.’s risk factors, click here.